Introduction {#Sec1}
============

Skin and soft tissue infections (SSTIs) are the consequence of a microbial invasion of the layers of the skin and underlying soft tissues \[[@CR1]\]. Complicated SSTIs (cSSTIs) represent more severe cases that involve deeper soft tissues and often require surgical treatment (e.g., infected ulcers, burns or major abscesses) \[[@CR2]\]. Moreover, associated comorbidities and microbial factors, particularly drug resistance, make the treatment of cSSTI more challenging \[[@CR3]\].

*Staphylococcus aureus* is the main causative pathogen of cSSTIs \[[@CR3]\]. Further, methicillin-resistant *S. aureus* (MRSA) complicates their treatment. The percentages of MRSA isolates reported in Europe range from 0.7% (Sweden) to 53.9% (Romania) \[[@CR4]\]. Prolonged hospital stay, economic burden and significant morbidity are associated with cSSTI due to MRSA \[[@CR5]\].

The glycopeptide vancomycin has been widely used for the treatment of MRSA infections, and its overuse has resulted in the emergence of vancomycin-intermediate and vancomycin-resistant *S. aureus* \[[@CR6]\]. As a consequence, the increase of the minimum inhibitory concentrations (MICs) of vancomycin for MRSA is now a major challenge \[[@CR7], [@CR8]\]. Increased relapse rates have been reported for MRSA infections with a high vancomycin MIC \[[@CR9]\].

Early therapy with anti-MRSA agents in cSSTI reduces in-hospital mortality, shortens length of hospital stay and decreases treatment cost \[[@CR10], [@CR11]\]. Therefore, the initial antibiotic treatment of cSSTI is frequently empirical before identification of the causative pathogen. Empirical coverage of both methicillin-susceptible *S. aureus* (MSSA) and MRSA infections is important, because failure of initial antibiotic therapy in cSSTI is significantly associated with worse clinical and economic outcomes \[[@CR12]\].

Daptomycin, a cyclic lipopeptide, displays rapid bactericidal activity against a wide range of Gram-positive pathogens including pathogens resistant to methicillin and vancomycin \[[@CR13]\]. Daptomycin is approved for the treatment of cSSTI (4 mg/kg/day), right-sided infective endocarditis due to *S. aureus* and bacteremia associated with cSSTI or right-sided infective endocarditis (6 mg/kg/day) \[[@CR14]\]. In two pivotal trials, the clinical success rate in patients with cSSTI was 83.4% \[[@CR15]\]. Of interest, daptomycin required a shorter duration of treatment than comparator antibiotics chosen by the study investigators \[[@CR15]\].

The European Cubicin^®^ Outcomes Registry and Experience (EU-CORE^SM^) collected data to evaluate daptomycin therapy in a real-world setting. The results from this registry during the first 2.5 years of clinical experience with in-patients with cSSTI or bacteremia have been published previously \[[@CR16]\]. The present analysis describes the final overall results of the EU-CORE registry (2006--2012) on the effectiveness and safety of daptomycin in the subgroup of patients with cSSTI.

Methods {#Sec2}
=======

Patients and Data Collection {#Sec3}
----------------------------

EU-CORE was a non-interventional, multicenter, retrospective registry designed to collect real-world outcome data from patients who had received at least one dose of daptomycin for the treatment of a Gram-positive bacterial infection between January 2006 and April 2012 with at least 30 days of safety follow-up. The study was performed across 18 countries in Europe (*n* = 12), Latin America (*n* = 5), and Asia (*n* = 1). The data were collected by local investigators using standardized case report forms. Patients who might have received daptomycin as part of a controlled clinical trial were excluded from the study. Details on methods of EU-CORE have been described elsewhere \[[@CR17]\]. For the present study, patients with cSSTI were selected and analyzed for treatment outcome and safety. An interim analysis of 373 patients with cSSTI selected from the first EU-CORE reporting period has been published (1127 patients enrolled between January 2006 and August 2008) \[[@CR16]\].

The protocol was approved by the health authority and the Institutional Review Board (IRB) or Ethics Committee (EC) in each country and written informed consent was obtained according to the requirements of the IRB or EC and/or the local data privacy regulations.

Clinical Outcomes and Safety {#Sec4}
----------------------------

Clinical outcomes at the end of daptomycin therapy were assessed for each of the patients included in the registry using the following protocol-defined criteria: cured, clinical signs and symptoms resolved, no additional antibiotic therapy was necessary, or infection cleared with a negative culture reported; improved, partial resolution of clinical signs and symptoms and/or additional antibiotic therapy was warranted; failed, inadequate response to daptomycin therapy, worsening or new/recurrent signs and symptoms, need for a change in antibiotic therapy, or a positive culture reported at the end of therapy; and non-evaluable, unable to determine response because of insufficient information. Clinical success was defined as patients who were cured or improved. The time to improvement was also recorded. The reasons for stopping daptomycin therapy and other antibiotics prescribed following daptomycin were also collected.

Safety assessments included reports of adverse events (AEs) and serious AEs (SAEs) up to 30 days after the end of daptomycin treatment along with their intensity and relationship to daptomycin. All AEs, regardless of seriousness or severity, were recorded.

Statistical Analysis {#Sec6}
--------------------

The safety population included all eligible patients with at least one safety assessment and the efficacy population included all eligible patients for whom clinical outcome was assessed.

Owing to the nature of the trial, inferential analyses were not performed and no formal statistical methodology other than simple descriptive statistics was used. Continuous variables were summarized as arithmetic mean, standard deviation, median and range; categorical variables were summarized by absolute and relative frequencies.

Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec7}
=======

Patient Demographic and Clinical Characteristics {#Sec8}
------------------------------------------------

Of the 6075 daptomycin-treated patients included in the EU-CORE registry, 1927 (31.7%) were diagnosed with cSSTI. Daptomycin therapy was completed without further antibiotic treatment for 1196 (62.1%) patients; 443 (23.0%) patients switched from daptomycin therapy (e.g., step-down to oral antibiotic therapy) and the remaining 288 (14.9%) patients discontinued treatment due to various reasons (AEs, *n* = 47 \[2.4%\]; treatment failure, *n* = 53 \[2.8%\]; unable to determine, *n* = 66 \[3.4%\]; and other or missing/unknown reasons, *n* = 122 \[6.3%\]).

Baseline demographics and clinical characteristics of these patients are summarized in Table [1](#Tab1){ref-type="table"}. The majority of patients were male (63.8%, *n* = 1230) and had a median age of 63.0 years (range 1--103). The most frequent underlying diseases were cardiovascular disease (58.1%, *n* = 1119) and diabetes mellitus (40.7%, *n* = 784). The most frequent cSSTIs were surgical site infections (SSIs; 34.9%, *n* = 673), wound infections (20.2%, *n* = 389), and diabetic foot infections (19.9%, *n* = 383).Table 1Demographic and clinical characteristicsCharacteristics*N* = 1927*n* (%)Age^a^ (years), median (range)63 (1--103) \<65 years1007 (52.3) ≥65 years919 (47.7) ≥75 years443 (23.0)Gender, male1230 (63.8)Ethnicity^b^, Caucasian1713 (88.9)Body weight (kg), median (range)77.0 (7--200)Significant underlying diseases (\>5%)^c^ Cardiovascular disease1119 (58.1) Diabetes mellitus784 (40.7) Renal disease278 (14.4) Pulmonary disease226 (11.7) Oncologic disease197 (10.2) Gastrointestinal disease174 (9.0)Complicated skin and soft tissue infections Surgical site infection673 (34.9)  Superficial incision236 (12.2)  Deep incision298 (15.5)  Organ/space139 (7.2) Wound389 (20.2) Diabetic foot383 (19.9) Deep ulcer189 (9.8) Major abscess186 (9.7) Diabetic ulcer (excluding diabetic foot infections)107 (5.6)Results are given as *n* (%) unless otherwise stated^a^Missing data for *n* = 1^b^Missing data for *n* = 34^c^Patients may have one or more underlying disease

Microbiology {#Sec9}
------------

Culture results were available for 82.0% (1580/1927) of patients; culture was positive for 82.1% (1297/1580) of them. The most frequent primary pathogens isolated from patients with cSSTI were *S. aureus* (51.9%, *n* = 673) and to a lesser degree coagulase-negative *Staphylococcus* (CoNS) (17.5%, *n* = 227), including *Staphylococcusepidermidis* (10.9%, *n* = 141; Table [2](#Tab2){ref-type="table"}). MRSA was reported in 31.5% (*n* = 408) of patients, whereas MSSA was isolated in 16.4% (*n* = 213) of patients with cSSTI.Table 2Primary pathogensCulture results and primary pathogens isolated*N* = 1927*n* (%)Available culture1580 (82.0) Negative culture283 (17.9) Positive culture1297 (82.1)  *Staphylococcus aureus*673 (51.9)   Methicillin resistant408 (31.5)   Methicillin susceptible213 (16.4)   Methicillin susceptibility unknown52 (4.0)  Coagulase-negative staphylococci227 (17.5)   *Staphylococcus epidermidis*141 (10.9)    Methicillin resistant15 (1.2)    Methicillin susceptible103 (7.9)    Methicillin susceptibility unknown23 (1.8)   Other86 (6.6)    Methicillin resistant12 (0.9)    Methicillin susceptible55 (4.2)    Methicillin susceptibility unknown19 (1.5)  *Enterococcus faecalis*71 (5.5)   Vancomycin resistant6 (0.5)   Non-vancomycin resistant48 (3.7)   Vancomycin susceptibility unknown17 (1.3)  *Enterococcus faecium*54 (4.2)   Vancomycin resistant9 (0.7)   Non-vancomycin resistant36 (2.8)   Vancomycin susceptibility unknown9 (0.7)  *Enterococcus* species13 (1.0)  Other^a^259 (20.0)^a^Other includes *Clostridium perfringens*, *Corynebacterium* spp., Gram-positive cocci, *Peptostreptococcus* spp., *Staphylococcus* spp. (coagulase not specified), *Streptococcus agalactiae* or group B streptococci, *Streptococcus dysgalactiae*, *Streptococcus dysgalactiae equisimilis*, *Streptococcus pyogenes* or group A streptococci, *Streptococcus* spp., viridans streptococci, Gram-negative bacilli, Gram-positive bacilli, Gram-negative cocci, fungi/yeast, and invalid/ambiguous pathogen code

Previous and Concomitant Antibiotic Therapy {#Sec10}
-------------------------------------------

Antibiotics prior to daptomycin therapy were received by 58.4% (*n* = 1126) of patients with cSSTI. Treatment failure (53.7%, *n* = 1034) was the most common reason for switching to daptomycin therapy, with failure most commonly occurring in patients treated with penicillins (11.9%, *n* = 229), fluoroquinolones (8.0%, *n* = 154), cephalosporins (7.0%, *n* = 134), or glycopeptides (6.6%, *n* = 127). Concomitant antibiotics were given more frequently to hospitalized patients (61.8%, *n* = 1190) than to outpatients (3.3%, *n* = 63). The most common concomitant antibiotics were carbapenems (22.9%, *n* = 442) and fluoroquinolones (15.6%, *n* = 301).

Daptomycin Prescribing Patterns {#Sec11}
-------------------------------

Daptomycin was prescribed as a first-line therapy in 34.2% (*n* = 659) of patients and as second-line therapy in 58.4% (*n* = 1126) of patients. The commonly prescribed doses of daptomycin in patients with cSSTI were 4 mg/kg/day (38.9%, *n* = 750) and 6 mg/kg/day (35.2%, *n* = 678). Of the 408 patients with MRSA infection, 32.1% (*n* = 131 were treated with 4 mg/kg/day and 30.6% (*n* = 125) with 6 mg/kg/day. However, among the 62 patients with MSSA infection, the most common dose of daptomycin was 6 mg/kg/day (59.7%), followed by 4 mg/kg/day (25.8%). Higher doses (\>6 mg/kg/day and ≤10 mg/kg/day) were received by 11.1% (*n* = 214) of patients and 0.2% (*n* = 3) of patients received doses \>10 mg/kg/day.

The total median duration of therapy in patients with cSSTI was 11 days with a range of 1--210 days \[10.0 days for outpatients (range 1--189 days); 10.0 days for in-patients (range 1--137 days) and 8.0 days for intensive care patients (range 1--90 days)\].

Clinical Outcomes {#Sec12}
-----------------

Clinical success rates were high for all doses. The overall clinical success rate (cured or improved) was 84.7% (*n* = 1632); 6.1% (*n* = 118) patients had treatment failure, and 9.2% (*n* = 177) patients were non-evaluable. High clinical success rates were observed in all subtypes of cSSTI. The clinical success rates for cSSTI subtypes were highest for diabetic ulcer infections (91.6%) and superficial incision SSIs (88.1%; Fig. [1](#Fig1){ref-type="fig"}). Overall, clinical success rates by primary pathogen were comparable as detailed in Fig. [2](#Fig2){ref-type="fig"}.Fig. 1Clinical outcome by cSSTI subtype. *cSSTI* complicated skin and soft tissue infection, *SSI* surgical site infectionFig. 2Clinical outcome by predominant primary pathogen. *CoNS* coagulase-negative *Staphylococcus,* *MRSA* methicillin-resistant *Staphylococcus aureus,* *MSSA* methicillin-susceptible *S. aureus*

The median time to improvement in patients with cSSTI was 4 days in patients receiving a daptomycin dose of 4 mg/kg/day (range 1--37) or 6 mg/kg/day (range 1--41).

Safety {#Sec13}
------

Overall, 10.5% (*n* = 203) of patients reported AEs including 2.4% (*n* = 46) with AEs possibly related to daptomycin (Table [3](#Tab3){ref-type="table"}). Daptomycin was discontinued due to an AE for 2.4% (*n* = 47) of patients.Table 3Summary of safety results of daptomycin treatmentSafety parameters*N* = 1927*n*(%)AEs203 (10.5)SAEs114 (5.9)Discontinuations due to AEs47 (2.4)AEs possibly related to daptomycin treatment46 (2.4) Skin and subcutaneous tissue disorders12 (0.6) General disorders and administration site conditions8 (0.4) Investigations7 (0.4)  Blood CPK increased7 (0.4) Musculoskeletal and connective tissue disorders2 (0.1)  Myalgia1 (0.1)SAEs possibly related to daptomycin treatment12 (0.6) General disorders and administration site conditions2 (0.1) Skin and subcutaneous tissue disorders2 (0.1) Investigations1 (0.1)  Blood CPK increased1 (0.1)Death3 (0.2)*AE* adverse event, *CPK* creatine phosphokinase, *SAE* serious AE

Increased blood creatine phosphokinase (CPK) was reported for 1.3% (*n* = 26) of patients and multi-organ failure for 1.2% (*n* = 24). SAEs were reported for 5.9% (*n* = 114) of patients, of whom 0.6% (*n* = 12) with SAEs possibly related to daptomycin.

Discussion {#Sec14}
==========

EU-CORE was a retrospective, multicenter registry, designed to collect real-world data on the use of daptomycin for Gram-positive infections. The results of the current analysis provide greater insights into the prescribing patterns of daptomycin and outcomes in cSSTI patients. In particular, a large proportion of the cSSTI population of EU-CORE was elderly and included patients with poor clinical conditions at baseline. Nevertheless, daptomycin treatment resulted in high clinical success rates in patients with different types of cSSTI, the majority of whom not responding to prior antibiotic therapies. As expected, the most frequently reported causative agent was *S.* *aureus* followed by CoNS. Overall, the present final analysis on 1927 patients of the cSSTI population of EU-CORE confirms the previous interim analysis on 373 patients with cSSTI \[[@CR16]\].

A majority of patients received either 4 mg/kg/day (38.9%), the approved dose of daptomycin for cSSTI without bacteremia, or 6 mg/kg/day (35.2%), which is approved for cSSTI with bacteremia. Doses \>6 mg/kg/day were received by 11.1% of patients. These high doses could reflect treatment of patients with serious or deep-seated cSSTIs (e.g., diabetic foot infection, major abscess). Moreover, recent guidelines recommend the use of high doses of daptomycin (from 8 to 10 mg/kg/day) in patients with moderate-to-severe or severe MRSA SSTIs associated with ischemia \[[@CR18]\].

The high clinical success rate (84.7%) observed in the present EU-CORE study is in line with the results observed in the CORE study \[[@CR19]\]. These results are also consistent with previously reported randomized clinical trials which assessed the efficacy of daptomycin in patients with cSSTI \[[@CR15], [@CR20]\]. In the two pivotal studies of Arbeit et al. \[[@CR15]\], the clinical success rate was 83.4% (372/446). In a randomized Phase IIIb trial, Konychev et al. \[[@CR20]\] observed a clinical success of 89.0% (65/73) in elderly patients (≥65 years) receiving daptomycin as first-line treatment for cSSTI. Quist et al. \[[@CR11]\] reported a clinical success of 91.4% (53/58) in a randomized clinical trial in patients with first-line treatment of daptomycin. In the meta-analysis of Wang et al. \[[@CR21]\] that included six randomized controlled trials, the overall clinical success in patients with cSSTI was 85.5% (630/737). Therefore, these results further support the use of daptomycin as a first-line treatment option for cSSTI.

Our results confirmed in real-world settings a comparable high effectiveness across infections caused by various pathogens, in particular MRSA. These results support the use of daptomycin as empiric treatment for cSSTI. Indeed, *S. aureus* is the most frequent pathogen causing cSSTIs and it is advantageous to start treatment with antibiotics that are effective against both MSSA and MRSA in settings with high MRSA rates. Early treatment of cSSTI caused by MRSA was associated with lower in-hospital mortality rates, shorter length of hospital stay and lower total costs \[[@CR10]\].

The current analysis displayed high clinical success rates in different types of cSSTI including diabetic foot infection, which is a serious, difficult-to-treat infection \[[@CR18]\]. These results support previous results from Joseph et al. who showed that success in patients with diabetic foot infection treated with daptomycin was higher in patients who had surgery and when initial therapy was daptomycin \[[@CR22]\]. In the exploratory study of Knapp et al. on the use of daptomycin in SSIs in 30 patients with superficial incision SSI and 30 patients with deep SSI, the clinical success rates were 100% and 92%, respectively \[[@CR23]\].

Daptomycin showed a favorable safety profile in this patient population without any new or unexpected safety findings. Study drug discontinuations due to AEs were infrequent. The blood CPK elevations were minimal.

The limitations of the present analysis were first related to the non-randomized and retrospective design of the study. Moreover, the treatment outcome was judged by the local investigators who were not blinded. No central laboratory was used and results of primary pathogens and their susceptibility could be different across the different centers. Another limitation is that many of the cSSTIs are mixed infections of both Gram-positive and Gram-negative bacteria. Daptomycin being specific for Gram-positive bacteria, the mixed cSSTI might not be cured completely, thus affecting the clinical success rate, and also increasing the need for concomitant antibiotic therapy. There was also no restriction on the use of concomitant antibiotics. Although the use of concomitant antibiotics complicated the data interpretation for both clinical outcome and safety of daptomycin, the treatment outcome associated with daptomycin reflected its use in real life. Despite these limitations, high levels of success were reported in the different centers that included patients in the registry with no stringent criteria. Indeed, the only criterion was daptomycin treatment for cSSTI. Therefore, patients with poor conditions who would have been excluded in a randomized trial were included in the registry.

Conclusions {#Sec15}
===========

Daptomycin treatment resulted in high clinical success rates in patients with different types of cSSTI, the majority of whom failed previous antibiotic therapy. Daptomycin was well tolerated and there were no new or unexpected safety findings.
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